Known targets — ChEMBL curated mechanism
ADRA1AADRA1BADRA1DDRD2HRH1HTR2AHTR2CSLC6A2
The experimentally established mechanism targets of Trimipramine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1A known ✓ | P35348 | 7/20 | 1.00 |
| ▸ | SLC6A2 known ✓ | P23975 | 6/20 | 1.00 |
| ▸ | HRH1 known ✓ | P35367 | 6/20 | 0.54 |
| ▸ | DRD2 known ✓ | P14416 | 4/20 | 0.54 |
| ▸ | HTR2A known ✓ | P28223 | 4/20 | 0.54 |
| ▸ | HTR2C known ✓ | P28335 | 4/20 | 0.54 |
| ▸ | ADRA1D known ✓ | P25100 | 1/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 9/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 7/20 | 1.00 |
| ▸ | DRD3 | P35462 | 7/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 7/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 6/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 6/20 | 1.00 |
| ▸ | LMNA | P02545 | 5/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 5/20 | 1.00 |
| ▸ | HTR1A | P08908 | 5/20 | 1.00 |
| ▸ | DRD1 | P21728 | 5/20 | 1.00 |
| ▸ | OPRM1 | P35372 | 5/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 5/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 4/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trimipramine SCHEMBL29373768 | 1.00 | SLC6A4 (1.00) | SLC6A4CHRM1ADRA1ADRD3KCNH2 | |
| Trimipramine SCHEMBL35144 | 1.00 | SLC6A4 (1.00) | SLC6A4CHRM1ADRA1ADRD3KCNH2 | |
| Trimipramine SCHEMBL5494378 | 1.00 | SLC6A4 (1.00) | SLC6A4CHRM1ADRA1ADRD3KCNH2 | |
| Trimipramine SCHEMBL4081184 | 0.98 | SLC6A4 (0.97) | SLC6A4CHRM1ADRA1ADRD3KCNH2 | |
| Trimipramine SCHEMBL30533075 | 0.98 | SLC6A4 (0.97) | SLC6A4CHRM1ADRA1ADRD3KCNH2 | |
| Trimipramine SCHEMBL7597041 | 0.98 | SLC6A4 (0.97) | SLC6A4CHRM1ADRA1ADRD3KCNH2 | |
| Trimipramine SCHEMBL29564386 | 0.91 | SLC6A4 (0.83) | SLC6A4CHRM1ADRA1ADRD3KCNH2 | |
| Trimipramine SCHEMBL6511858 | 0.90 | CHRM1 (0.82) | SLC6A4CHRM1ADRA1ADRD3KCNH2 | |
| Trimipramine SCHEMBL6511859 | 0.90 | CHRM1 (0.82) | SLC6A4CHRM1ADRA1ADRD3KCNH2 | |
| SCHEMBL2615203 | 0.89 | LMNA (0.80) | SLC6A4CHRM1ADRA1ADRD3KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 4075 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12617809-B2 | Cardioprotective lipid and method of use | SIGNPATH PHARMA, INC. (US) | 2026-05-05 | — | — | US | claimed |
| EP-4731194-A1 | MATERIALS AND METHODS FOR MITIGATING THE PRESENCE OF NITROSAMINES IN PACKAGING USING AN ACTIVE AGENT | CSP Technologies, Inc. (US) | 2026-04-29 | — | — | EP | claimed |
| US-20260027337-A1 | TRANSDERMAL DRUG DELIVERY DEVICES AND METHODS | MORNINGSIDE VENTURE INVESTMENTS LTD (MC) | 2026-01-29 | — | — | US | claimed |
| US-12515030-B2 | Transdermal drug delivery devices and methods | MORNINGSIDE VENTURE INVESTMENTS LIMITED (MC) | 2026-01-06 | — | — | US | claimed |
| WO-2025264260-A1 | MATERIALS AND METHODS FOR MITIGATING THE PRESENCE OF NITROSAMINES IN PACKAGING USING AN ACTIVE AGENT | CSP TECHNOLOGIES, INC. (US) | 2025-12-26 | — | — | WO | claimed |
| EP-4658278-A1 | SELECTIVE FIASMA TREATMENT | Valo Health, Inc. (US) | 2025-12-10 | — | — | EP | claimed |
| US-12474326-B2 | Treatment methods having reduced drug-related toxicity and methods of identifying the likelihood of patient harm from prescribed medications | TABULA RASA HEALTHCARE, INC. (US) | 2025-11-18 | — | — | US | claimed |
| US-20250339483-A1 | EXTRACELLULAR VESICLES FROM MICROALGAE, THEIR BIODISTRIBUTION UPON INTRANASAL ADMINISTRATION, AND USES THEREOF | AGS THERAPEUTICS SAS (FR) | 2025-11-06 | — | — | US | claimed |
| EP-4608424-A1 | EXTRACELLULAR VESICLES FROM MICROALGAE, THEIR BIODISTRIBUTION UPON INTRANASAL ADMINISTRATION, AND USES THEREOF | AGS Therapeutics SAS (FR) | 2025-09-03 | — | — | EP | claimed |
| EP-4590681-A1 | CARDIOPROTECTIVE LIPID AND METHOD OF USE | Signpath Pharma, Inc. (US) | 2025-07-30 | — | — | EP | claimed |
| US-20020006440-A1 | Rapid-melt semi-solid compositions, methods of making same and methods of using same | CAPRICORN PHARMA, INC. | 2002-01-17 | — | — | US | claimed |
| WO-2002002081-A1 | RAPID-MELT SEMI-SOLID COMPOSITIONS, METHODS OF MAKING SAME AND METHODS OF USING SAME | CAPRICORN PHARMA, INC. (US) | 2002-01-10 | — | — | WO | claimed |
| WO-2001098291-A2 | 1,3-BIS-(SUBSTITUTED-PHENYL)-2-PROPEN-1-ONES AND THEIR USE TO TREAT VCAM-1 MEDIATED DISORDERS | ATHEROGENICS, INC. (US) | 2001-12-27 | — | — | WO | claimed |
| WO-2001047507-A2 | COMBINATIONS OF RECEPTOR TYROSINE KINASE INHIBITOR WITH AN A1-ACIDIC GLYCOPROTEIN BINDING COMPOUND | NOVARTIS AG (CH) | 2001-07-05 | — | — | WO | claimed |
| US-6228875-B1 | ADMINISTERING DERIVATIVE OF ALANINE OR SERINE AS AGONIST OF NMDA RECEPTOR; ALZHEIMER*S DISEASE, PSYCHOLOGICAL AND NERVOUS SYSTEM DISORDERS, SCHIZOPHRENIA; COGNITION ACTIVATORS | THE GENERAL HOSPITAL CORPORATION | 2001-05-08 | — | — | US | claimed |
| EP-1073470-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2001-02-07 | — | — | EP | claimed |
| EP-1073432-A2 | USE OF GLYCINE SITE AGONISTS OR GLYCINE UPTAKE INHIBITORS FOR TREATING NEUROPSYCHIATRIC DISORDERS | THE GENERAL HOSPITAL CORPORATION (US) | 2001-02-07 | — | — | EP | claimed |
| WO-2000048636-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2000-08-24 | — | — | WO | claimed |
| WO-1999052519-A2 | METHODS FOR TREATING NEUROPSYCHIATRIC DISORDERS | THE GENERAL HOSPITAL CORPORATION (US) | 1999-10-21 | — | — | WO | claimed |
| US-5256409-A | Complexing two drug haptens to carrier protein | THERAPEUTIC ANTIBODIES, INC. (US) | 1993-10-26 | — | — | US | claimed |